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ABSTRACT
ROLE OF INTERLEUKIN-17 IN THE ADAPTIVE
IMMUNE RESPONSE IN LYME ARTHRITIS
by
Emily M. Siebers
The University of Wisconsin-Milwaukee, 2012
Under the Supervision of Dr. Dean T. Nardelli

Lyme arthritis is a devastating symptom of Lyme borreliosis that causes severe
inflammation of the synovial joints. Interleukin-17 (IL-17) plays a role in the
pathogenesis of various arthritides, including, possibly, Lyme arthritis, by causing
the expression of genes involved in the production of inflammatory cytokines by
synoviocytes. However, the cellular sources of IL-17 in the context of Borrelia
burgdorferi infection are unknown, as are the effects of these cells on the
development of arthritis and stimulation of humoral immunity through the
production of borreliacidal antibodies. Using multiple models of Lyme arthritis, the
hypothesis that IL-17 produced by CD4+ cells contributes to the inflammation
associated with B. burgdorferi infection and is associated with an increase in
borreliacidal antibody production was tested. Serum IL-17 levels were increased
during Borrelia infection, especially at the time of peak swelling. Neutralization of
interferon-gamma increased these IL-17 levels, and the addition of anti-CD4
antibodies to cultures of stimulated cells isolated during peak swelling reduced
IL-17 levels. In addition, a role for IL-10 in the production of IL-17 was
demonstrated. Furthermore, increased IL-17 was associated with an increase of
ii

borreliacidal antibodies. These findings suggest CD4+ cells (possibly T cells)
contribute to the production of IL-17 following infection with B. burgdorferi and
that levels of this cytokine may affect borreliacidal antibody production.
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CHAPTER 1: INTRODUCTION
I. Background
1. Lyme Borreliosis
Lyme borreliosis is the most common tick-borne disease in the United States,
affecting tens of thousands of Americans infected with the spirochete Borrelia
burgdorferi annually (1). It is a multi-stage, multi-symptom disease that is often
misdiagnosed due to its vague clinical presentation. The main manifestations of
Lyme borreliosis involve the neurological, cardiovascular, and musculoskeletal
systems, with symptoms increasing in severity in the absence of antimicrobial
therapy. However, a small proportion of genetically predisposed individuals
continue to exhibit symptoms despite receiving, in accordance with guidelines
established by experts in the field, antimicrobial therapy considered sufficient for
clearing infection (2, 3). The cause of these persistent, chronic symptoms is a
source of great contention in the field; among the most frequently considered
theories are survival of the microbe in connective tissues, retention of antigenic
microbial fragments, and infection-induced autoimmunity (4). Regardless, the
pathology of Lyme borreliosis is caused by the immune response to infection, as
B. burgdorferi does not secrete toxins or other products that induce tissue
damage. Therefore, in the absence of effective antimicrobial treatment, antiinflammatory therapeutic interventions would be a significant means for reducing
morbidity of Lyme borreliosis.
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Lyme borreliosis is endemic to several regions of the United States, including the
Northeast, Mid-Atlantic, Upper Midwest, and Far West. Lyme borreliosis is
transmitted by the bite of the Ixodes tick and is endemic to regions in which these
tick vectors, as well as their animal reservoirs, live. In the northeastern and upper
midwestern United States, B. burgdorferi is transmitted to humans by I.
scapularis. These ticks become infected with the spirochete when they take a
blood meal from infected small rodents (typically mice) and other mammalian
hosts, such as deer and foxes. In the western United States, lizards occasionally
serve as a reservoir for the bacteria (5) and are transmitted via I. pacificus.
Moreover, birds have been identified as carriers of B. burgdorferi, providing a
means for the bacteria to spread farther distances (6). Transmission most
commonly occurs during the nymphal stage of tick development, when they are
relatively small and are difficult to observe (2). The greatest onset of illness
occurs between the months of May and August, when ticks have reached this
stage of development. Though relatively rare, adult ticks are also capable of
causing infection (2). In endemic areas, up to 30% of Ixodes ticks may be
infected (7). An infected tick must be attached to its host for several days in order
to transmit B. burgdorferi effectively (8). Unfortunately, patients diagnosed with
Lyme borreliosis often do not recall having been bitten by a tick.

2. Stages of Disease, Diagnosis, and Therapeutic Measures
Untreated Lyme borreliosis is characterized by three phases: early infection,
disseminated infection, and late infection. Most early symptoms of Lyme
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borreliosis are typically vague, presenting as flu-like symptoms such as fever,
headache, fatigue, and joint and muscle aches one to two weeks after the bite of
an infected tick. However, diagnosis in this early stage is facilitated greatly by a
skin lesion called erythema migrans (EM). EM is a painless, flat rash that
radiates from the site of the tick bite and often exhibits central clearing,
resembling a bull’s-eye. Approximately 70% of infected individuals develop EM
and, when it is observed in an endemic area or following a known tick bite, it is
usually considered diagnostic (2). However, due to the rash’s varied appearance
and occasionally inconspicuous anatomical location, EM is often not observed by
the patient or physician. Moreover, since the other symptoms of this early phase
are constitutional, a diagnosis of Lyme borreliosis frequently is not considered
and the infection progresses without treatment.

The second stage of Lyme borreliosis involves dissemination throughout the
body weeks to months after infection and manifests in more severe symptoms.
Secondary EM lesions are commonly observed at locations distal from the site of
infection (2). Atrioventricular block, as well as neurological abnormalities such as
numbness or tingling of the extremities, visual disturbances, and partial paralysis
of facial muscles (9, 10), are commonly observed. Patients frequently develop
more pronounced musculoskeletal symptoms, including pain and swelling of the
joints and tendons (2). These symptoms may be exacerbated in late, persistent
Lyme borreliosis, which occurs months to years after the initial onset of disease.
Patients may experience profound neurological symptoms, including memory
loss, fluctuations in mood, and peripheral neuropathy. In addition, 60% of

4
infected individuals at this stage exhibit Lyme arthritis, which is characterized by
severe inflammation of the synovial tissues, ligaments, and tendons (2). Despite
antimicrobial treatment, some individuals develop a chronic, severe, destructive
arthropathy characterized by erosion of cartilage and bone (11).

Although frequently severe, most of the symptoms of Lyme borreliosis are shared
by numerous other conditions and, therefore, often confound physicians and
patients. Difficulties in diagnosis are compounded by the fact that suspected
cases must fit several criteria before they are accepted as actual cases of
disease. For example, in the absence of serodiagnostic confirmation, the EM
lesion must be at least 5 centimeters in diameter and be accompanied by at least
one late manifestation of disease (12). Current laboratory standards call for
serodiagnostic confirmation using a two-tiered system: a screening enzymelinked immunosorbent assay (ELISA), followed by a confirmatory Western blot
that is deemed positive based on observation of immunoglobulin M or
immunoglobulin G antibodies against a certain number of borrelial antigens (3).
The infection can be cleared with antibiotics; the current standard of treatment is
two to three weeks of oral doxycyline (3). However, in cases of prolonged
infection or more severe symptoms, intravenous ceftriaxone may be prescribed
(3). Subsequent or longer treatments may be needed if the symptoms persist
beyond the initial course of antibiotics. Delayed treatment increases the
likelihood of developing chronic symptoms, such as Lyme arthritis.
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3. Lyme Arthritis
Lyme arthritis is among the most common clinical manifestations of Lyme
borreliosis, affecting approximately 60% of individuals infected with B. burgdorferi
(2). In humans, intermittent episodes of arthritis typically begin in the weeks or
months following infection and may continue for years. Antibiotic treatment
typically leads to successful resolution of disease; however, for a small subset of
patients, arthritis persists despite several courses of antibiotics and negative
polymerase chain reaction results from synovial tissue and fluid (13). These
patients, who continue to have proliferative synovitis, are said to have antibioticrefractory, or slow-resolving, arthritis (13). In addition to slower resolution of joint
inflammation, patients with antibiotic-refractory Lyme arthritis also have higher
levels of pro-inflammatory cytokines and lower levels of anti-inflammatory
cytokines in the synovial fluid during the entire course of disease, including after
treatment, when compared to patients with antibiotic-responsive Lyme arthritis
(14, 15).

Despite a well-defined clinical course, the immune mechanisms responsible for
the development and persistence of Lyme arthritis are not fully understood. As a
result, very few treatment options exist. After antibiotic therapy has been used to
clear the spirochete infection, the current recommended therapy is the use of
non-steroidal

anti-inflammatory

agents

(3).

Understanding

the

immune

mechanisms involved during the course of arthritis, as well as during the course
of bacterial infection, is essential for the development of novel treatments.
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4. Innate Immune Events of Lyme Arthritis
Several innate immune cells are responsible for both the inflammatory response
observed in early-stage disease and the initial containment of B. burgdorferi. Due
to the microbe’s ability to bind to various connective tissues (11, 16), an
inflammatory response is often observed in sites such as the skin, ligaments,
tendons, and synovial tissues. Large numbers of macrophages and dendritic
cells, but not neutrophils, are present in the primary EM rash, which is the
location of initial infection in the skin (17). Interaction of macrophages with B.
burgdorferi has been shown to cause the production of several inflammatory
molecules, including interleukin-1-beta (IL-1β), interleukin-6 (IL-6), tumor
necrosis factor-alpha (TNF-α), and nitric oxide (18). Macrophages are likely
activated via Toll-like receptor 2, which binds to the lipoproteins found on the
surface of B. burgdorferi (19). In addition, macrophages and dendritic cells are
significant activators of the adaptive immune response to B. burgdorferi.

In addition, neutrophils play a major role in the inflammatory response to B.
burgdorferi. Activation of these cells by B. burgdorferi also causes the production
of IL-1β and TNF-α (3, 20). Importantly, these cells are found in large numbers in
the synovial tissues of infected patients (4) and are known producers of the
inflammatory cytokine interleukin-17 (IL-17) (21). Moreover, natural killer (NK)
cells, through the production of interferon-gamma (IFN-γ), have been shown to
contribute to pathology in both C3H and C57BL/6 mice (22, 23), the most
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commonly used animal models for Lyme arthritis. However, NK cells may not be
completely required for disease to develop, since their removal in infected mice
did not reduce the severity of arthritis (22, 23).

These innate inflammatory mediators play a significant role in the initial response
to the spirochete and the early events of Lyme arthritis. It is imperative to identify
novel therapies to minimize inflammation at this early stage without disrupting the
ability of the immune response to contain the infection.

5. T Cell Involvement in Lyme Arthritis
While innate immunity is involved in early pathology, the later-stage events
observed in humans, typically months to years after infection, involve events of
adaptive immunity. Synovial lesions in patients with Lyme arthritis contain T
helper cells with B cells intermixed (24). Due to their predominant presence in
synovial lesions, T cells have long been investigated as a contributor to Lyme
arthritis. Traditionally, later-stage Lyme arthritis has been considered to be
caused by the inflammatory effects of type 1 T helper (Th1) cells and their
signature cytokine, IFN-γ (25, 26, 27). Increased numbers of Th1 cells and levels
of IFN-γ have been observed in the synovial tissue, synovial fluid, and peripheral
blood of humans with Lyme arthritis (28, 29, 30). Th1 cells and IFN-γ are also
present in experimental mice that develop Lyme arthritis after infection with B.
burgdorferi (25).

8
However, studies using mice genetically deficient in IFN-γ, its receptor, or its
signaling pathway have demonstrated that the cytokine is not absolutely required
for the development of Lyme arthritis (29, 30, 31). Still, T helper cells are involved
in disease, since animals depleted of CD4+ T cells before infection with B.
burgdorferi develop minimal inflammatory changes (32). Conversely, transfer of
Borrelia-primed CD4+ T cells into recipient mice increases pathology following
infection (33). Collectively, these results suggest that CD4+ T cell-associated
inflammatory factors in addition to IFN-γ may contribute to the pathogenesis of
Lyme arthritis.

Another subset of helper T cell, type 17 T helper (Th17) cells, are characterized
by production of the inflammatory cytokine IL-17 (34) and may also contribute to
the development of Lyme arthritis. Production of IL-17 is stimulated by borrelial
lipoproteins (35) and induces other cells to generate a cascade of inflammatory
mediators capable of damaging host tissue, including that observed in chronic
arthritis. The inflammatory capacity of IL-17 is demonstrated by its stimulation of
IL-6, IL-1β, TNF-α, and prostaglandins from various cell types, as well as by its
role in contributing to collagenase activity and osteoclast formation (36). IL-17 is
an important mediator of several arthritides, including rheumatoid arthritis (37),
juvenile idiopathic arthritis (38), antigen-induced arthritis (39), and collageninduced arthritis (CIA) (40). Th17 cells play a major role in the development of
autoimmunity, in part due their production of interleukin-21 (IL-21), which may act
in a positive feedback loop to maintain a Th17 response (41). Th17 cells also
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play a significant role in the immune response against fungal and bacterial
pathogens (42).

Research has suggested that Th17 cells play a potentially pathogenic role
following infection with B. burgdorferi. Neutralization of IL-17 in B. burgdorferiinfected mice reduces paw swelling and prevents arthritis (43). In addition,
simultaneous neutralization of IL-6 and transforming growth factor-β (TGF-β), the
major differentiation factors for Th17 cells in vitro (44), protects mice from Lyme
arthritis (45). Moreover, borrelial antigens induce dendritic cells to secrete
interleukin-23 (IL-23) (46), the major survival factor for Th17 cells (44).
Neutralization of IL-23 prevents the development of Lyme arthritis in B.
burgdorferi-infected mice and reduces the production of IL-17 from stimulated
immune cells (47). Furthermore, borrelial lipoproteins stimulate the in vitro
production of IL-17 from T cells isolated from the synovia of humans with Lyme
arthritis (48), and Th17 cells have been isolated directly from such individuals
(28). However, the direct role of these cells in mediating pathology has not been
determined. Significantly, it was shown that neutralization of IL-17 in a mouse
model of Lyme arthritis, in addition to preventing the development of arthritis,
also resulted in an increase in the number of CD4+CD25+ T cells with
immunoregulatory function (49).

Current research suggests a role for not just one, but several types of T cells in
Lyme arthritis. As a result, interactions between the cell types may be involved in
the development of disease. For example, Th1 and Th17 cells display an
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antagonistic relationship (50). Through the production of IFN-γ, Th1 cells inhibit
the proliferation of Th17 cells (50). Likewise, Th17 cells inhibit Th1 cells via the
production of IL-17 (50). However, despite the ability to counter-regulate each
other, Th17 and Th1 cells can also display a cooperative relationship. Th17 cells
can develop into a Th1-like cell (51) and have been shown to produce IFN-γ in
response to an infectious stimulus (52). The relationship between these two cell
types may influence the cytokine profile that leads to the development of arthritis.
This altered cytokine profile occurs in CIA-resistant mice, which have a higher
ratio of IL-17 to IFN-γ than CIA-susceptible mice (53).

The developmental relationships of these T cells are not straightforward. For
instance, Th1 cells also influence the development of regulatory T (Treg) cells.
IFN-γ, produced by Th1 cells, is involved in the conversion of CD4+CD25- helper
T cells into CD4+Foxp3+ Treg cells via an increase in Foxp3 expression (54).
Also, Th17 cells may produce interleukin-10 (IL-10), an anti-inflammatory
cytokine typically produced by Treg cells (52). Taken together, these findings
suggest an intertwined role of multiple T cell types in the development of Lyme
arthritis that may be dependent on the cytokine profile expressed following
infection with B. burgdorferi.

6. Animal Models of Lyme Arthritis
Traditionally, Lyme arthritis has been studied using C3H mice, which are
considered genetically “arthritis susceptible” (55) following needle infection with
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particularly virulent strains of B. burgdorferi (56). In this model, the arthritis that
ensues manifests days after infection and primarily involves inflammatory events
of innate immunity. However, Lyme arthritis in humans develops weeks to years
following infection, suggesting that adaptive immunity plays a significant role in
disease. In support of this, synovial fluid of human Lyme arthritis patients
contains CD4+ T cells specific for the likely arthrogenic borrelial antigen outer
surface protein A (OspA) (57). This finding provides support that cells of adaptive
immunity–specifically, T cells–are significant contributors to human Lyme
arthritis. A murine model of Lyme arthritis–the Borrelia-vaccination and -infection
model–incorporates the activity of primed and activated T cells in inducing
disease, which is observed in humans with later-stage Lyme arthritis.

Mice are vaccinated with heat-killed B. burgdorferi in aluminum hydroxide in
order to prime T cells. Three weeks later, they are infected with a heterologous
strain of Borrelia that is capable of inducing activation of vaccine-primed T cells
while evading the protective antibody response generated by vaccination. This
model exhibits an antigen-specific reaction to viable Lyme spirochetes (58, 59)
and is dependent on CD4+ T cells (33). Infection with homologous spirochetes
induces arthritis if infection occurs prior to development of protective antibodies
(59). However, infection with a heterologous strain allows for a degree of
pathology more suitable for recognition of the effects of immune modulators such
as anti-cytokine antibodies. A homologous infection strain can also cause arthritis
following vaccination, as long as infection occurs after the vaccine-induced
protective antibody response has declined sufficiently. However, this may take as
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long as two months (60) and could vary between individual animals. In addition to
reflecting events of adaptive immunity, another benefit of this model is that
different combinations of Lyme spirochetes can be used for vaccination and
infection. Also, this model can induce arthritis in C57BL/6 mice, which are
considered “genetically resistant” to developing arthritis following infection with B.
burgdorferi, as observed in the Borrelia-infection model (23).

7. Borreliacidal Antibody Response
An antibody response is required for eliminating B. burgdorferi and resolving the
inflammatory response following infection. In particular, antibodies with the ability
to specifically recognize and stimulate killing of the infecting borrelial strain–
borreliacidal antibodies–are considered vital to the clearance of the spirochete
(61). Early studies showed that injection of serum from B. burgdorferi-infected
rabbits was able to protect against establishment of infection in hamsters (62). It
was then shown that injection of Borrelia-immune serum after infection protected
hamsters from developing arthritis (63). Stimulation of high levels of borreliacidal
antibodies that are maintained for long periods of time are required for effective
vaccines against Lyme borreliosis (64). In the mid-1990s, human trials of Lyme
vaccines required patients to receive three doses of OspA (65, 66). While the
vaccine was effective against infection during the observation period of the study,
concerns were raised about the vaccine’s ability to prevent late-stage
manifestations of disease. The reports of these human trials did not describe for
how long high borreliacidal antibody titers lasted, and this uncertainty may have
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contributed to the removal of the Lyme vaccine from the marketplace (64). A
reliable assay to detect borreliacidal antibody activity is well established (67).

Borreliacidal antibodies against an antigen differ from total antibodies against
that antigen in important ways. Padilla, et al. (60) showed that humans
vaccinated with OspA produced borreliacidal antibodies that waned within weeks.
However, the titers of total antibodies directed against OspA remained high for
months (60). This difference highlights the importance of identifying factors that
sustain borreliacidal antibody production, as life-long protective immunity does
not develop after B. burgdorferi infection. It has also been shown that
borreliacidal antibody titers decrease as arthritis resolves, indicating a possible
relationship between arthritis-inducing inflammatory cytokines and the antibody
response (61). In addition, levels of borreliacidal antibodies decrease as B.
burgdorferi is cleared from tissues, suggesting that borreliacidal antibodies may
serve as an indicator of the state of infection (68). This suggests that immune
factors which increase the borreliacidal antibody response may be useful as a
therapy against infection with B. burgdorferi.

II. Hypothesis and Specific Aims
Arthritis is a major symptom of Lyme disease, causing inflammation and, in some
cases, degradation of the synovial joints. A role for IL-17 in the development of
experimental Lyme arthritis has been established. IL-17 also plays a role in the
pathogenesis of various arthritides by stimulating the expression of genes
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involved in the production of inflammatory cytokines, specifically in synoviocytes.
However, while Th17 cells have been shown to produce IL-17 in response to
exposure with B. burgdorferi in vitro, it is currently unknown whether T cells are
the primary cellular source of IL-17 that mediates inflammation. In addition, the
effects of IL-17 modulation on the stimulation of humoral immunity require further
examination. The overall objective of this study is to elucidate the contributions of
IL-17-producing CD4+ cells in the development of B. burgdorferi-induced arthritis
and IL-17 in the stimulation of the borreliacidal antibody response. Identifying
sources of IL-17 in Lyme arthritic mice may help reveal immune mechanisms that
drive the pathogenesis of disease and may lead to identification of novel
therapeutic targets. Furthermore, understanding the effect of IL-17-producing
cells on induction of borreliacidal antibodies is essential for the development of
safe vaccines that provide protection against B. burgdorferi infection.

The hypothesis of this thesis is: IL-17 produced by CD4+ cells contributes to the
inflammation associated with B. burgdorferi infection and is associated with an
increase in borreliacidal antibody production.

The following specific aims are pursued to test this hypothesis:

1. Establish CD4+ cells as a source of IL-17 following infection with B.
burgdorferi. The working hypothesis of this aim is: CD4+ cells are a
significant source of IL-17 during B. burgdorferi-induced inflammation.
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2. Establish a relationship between IL-17 levels and borreliacidal
antibody production. The working hypothesis of this aim is: Increases in
IL-17 are associated with an increase in borreliacidal antibody titers
following infection with B. burgdorferi.
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CHAPTER 2: MATERIALS AND METHODS
I. Mice
Male, 6-to-12 week old wild-type C3H/HeN mice were purchased from Charles
River Laboratories (Wilmington, MA). Male and female, 6-to-12-week old, IL-10deficient or wild-type C57BL/6 mice were obtained from J.-A. Lyons (University of
Wisconsin-Milwaukee). All mice were housed in micro-isolator cages in a
humidity- and temperature-controlled environment under a 12-hour light/dark
schedule at the University of Wisconsin-Milwaukee animal facility. Food and
water were provided ad libitum. Experimental protocols were reviewed and
approved by the University of Wisconsin-Milwaukee Institutional Animal Care and
Use Committee.

II. Vaccination of Mice
Borrelia bissettii (formerly B. burgdorferi strain C-1-11) organisms were provided
by S. M. Callister (Gundersen Lutheran Medical Center, La Crosse, WI). These
organisms were heat-inactivated by incubating for 30 minutes in a 56°C water
bath. Successful inactivation was determined by observing a lack of motility
under dark-field microscopy. In addition, these organisms failed to grow in
Barbour-Stoenner-Kelly (BSK) medium at 34°C for 7 d ays. The heat-inactivated
organisms were then washed 4 times by centrifuging with phosphate-buffered
saline (PBS; 7000g, 10 minutes), followed by resuspension in PBS. The heatinactivated organisms were then combined with 1% aluminum hydroxide to
create a 4 x 106 organisms/mL vaccine preparation. Mice were injected
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subcutaneously in each inguinal region with 0.25 mL vaccine preparation while
under anesthesia with isoflurane in a nose-and-mouth cup.

III. Infection of Mice
B. burgdorferi strain 297 organisms were provided by S. M. Callister (Gundersen
Lutheran Medical Center, La Crosse, WI). Organisms were grown at 34°C for 3-6
days in BSK medium. Twenty-one days after vaccination, mice were injected
subcutaneously in each hind paw with 106 viable B. burgdorferi strain 297
organisms in 0.05 mL BSK medium while anesthetized with isoflurane in a noseand-mouth cup. Control groups were created by sham-infecting vaccinated mice
(injecting with BSK medium alone) or injecting vaccinated mice with heat-killed B.
burgdorferi strain 297 organisms in BSK medium. In other studies, nonvaccinated mice were infected with B. burgdorferi strain 297 in a similar manner.
Control groups were created by sham-infecting non-vaccinated mice (injecting
with BSK medium alone).

IV. Antibody Treatment
Monoclonal antibody specific for mouse IFN-γ (clone 37895) was purchased from
R & D Systems (Minneapolis, MN). The antibodies were resuspended in PBS to
achieve a concentration of 50 µg/mL. One hour after infection, mice were injected
with 2.5 µg (0.05 mL) anti-IFN-γ antibody subcutaneously in each hind paw while
anesthetized with isoflurane in a nose-and-mouth cup. Mice were then injected
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daily for 7 days. Control mice were injected similarly with either an isotype control
antibody in PBS or PBS alone.

V. Assessment of Inflammation
Hind paw swelling was assessed by measuring the width and thickness of the
tibiortarsal joints using a digital caliper (Marathon). These measurements were
averaged to provide a measure for each paw. Hind paw swelling was measured
immediately prior to infection with B. burgdorferi (or injection with BSK medium)
and then every other day thereafter. Measurements were obtained prior to
injection of antibodies, isotype control antibodies, or PBS.

VI. Cell Culture
On days 8 or 10 after infection (the days of peak hind paw swelling), inguinal and
popliteal lymph nodes and/or spleens were harvested from B. bissettii-vaccinated
mice injected with live B. burgdorferi 297, heat-killed B. burgdorferi 297, or BSK
medium. Single-cell suspensions were generated by passing cells through a
nylon mesh screen into cold Dulbecco’s Modified Eagle’s Medium or Roswell
Park Memorial Institute 1640 medium. 1 x 106 cells were incubated at 37°C in 5%
CO2 with or without 1 x 105 viable B. burgdorferi strain 297 organisms and with or
without 5 µg (5µL) anti-mouse CD4 antibodies (clone GK1.5; eBioscience, San
Diego, CA). Supernatants were collected after 6 and 24 hours of incubation.
Controls consisted of cells incubated without antibodies or organisms.
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VII. ELISA
Blood was collected by intracardiac puncture on days 8, 10, or 12 after infection.
Levels of serum IL-17 and IFN-γ were determined using IL-17A and IFN-γ ELISA
Ready-Set-Go!

Kits

(eBioscience,

San

Diego,

CA)

according

to

the

manufacturer’s directions. Cytokine levels were also assessed from cell culture
supernatants. The plates were read at 450nm and values were expressed as
optical densities. Standard curves were created and used to calculate pg
cytokine/mL for each sample. Cytokine levels not detectable by ELISA were
given a value of 0.00 pg/mL for statistical purposes.

VIII. Borreliacidal Antibody Assay
Sera or cell culture supernatants were used to determine titers of borreliacidal
antibodies. Samples of serum or supernatant were pooled within a group. Each
pooled sample was diluted 1:20 in PBS, passed through a 0.2 µm filter, and then
further diluted serially, 1:40 to 1:10,240, with PBS. The diluted specimens were
heated at 56°C for 30 minutes to inactivate complemen t and then cooled to 35°C.
The complement-inactivated specimens were incubated with 104 viable B.
burgdorferi 297 organisms and 20 µL of sterile guinea pig complement (SigmaAldrich; St. Louis, MO) in PBS for 24 hours. The presence of viable microbes
was then observed in 20 fields using dark-field microscopy. The titer of
borreliacidal antibody was considered the reciprocal of the final dilution in which
motile B. burgdorferi was observed. Controls contained B. burgdorferi 297 and
complement (without sample), B. burgdorferi 297 and PBS (without complement
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or sample), and B. burgdorferi 297 and PBS added to a sample (without
complement). A four-fold increase in borreliacidal antibody titer was considered
significant.

IX. Statistics
The results of some studies were expressed as mean ± standard error of the
mean (SEM) and analyzed using a two-tailed Student's t-Test to determine the
level of significance. Other data were analyzed by one-way analysis of variance
(ANOVA) followed by the Tukey-Kramer post-hoc test. All P-values were
calculated with the alpha level set at 0.05 prior to initiation of experiments.
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CHAPTER 3: RESULTS
I. Specific Aim 1: Establish CD4+ cells as a source of IL-17 following
infection with B. burgdorferi.
1. Effects of anti-IFN-γ antibody administration on hind paw swelling
This study was performed to assess the requirement of IFN-γ for inflammation
following B. burgdorferi infection. Non-vaccinated, B. burgdorferi-infected C3H
mice were injected with anti-IFN-γ or isotype-control antibodies, and the swelling
of the hind paws was measured throughout infection. Control mice were injected
with BSK medium, followed by injections with PBS. The B. burgdorferi-infected
mice administered isotype-control antibodies developed greater swelling of the
hind paws than non-infected control mice. Swelling was observed on day 2 after
infection, peaked at day 9, and gradually subsided (Figure 1). This swelling
remained greater than that observed in control mice until day 17 after infection. In
addition, B. burgdorferi-infected mice injected with anti-IFN-γ antibodies exhibited
a pattern of hind paw swelling similar to that of infected mice injected with isotype
control antibodies. An additional group of B. burgdorferi-infected mice injected
daily with PBS alone developed swelling not significantly different than that of
infected mice injected with isotype control antibodies (data not shown).
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Figure 1. Administration of anti-IFN-γ antibody does not affect paw swelling in
B. burgdorferi-infected C3H mice. Mice were infected with B. burgdorferi 297
and treated with anti-IFN-γ antibody (n=10) or an isotype control antibody (n=10)
for 7 days. Non-infected control mice (n=10) were treated with PBS. Error bars
indicate the SEM.

2. Serum levels of IL-17 following treatment with anti-IFN-γ antibodies
Th1 and Th17 cells are known to act antagonistically through IFN-γ and IL-17,
respectively. To determine the effect of anti-IFN-γ antibody treatment on IL-17
production, sera were collected from B. burgdorferi 297-infected C3H mice
treated with anti-IFN-γ or isotype control antibodies on days 7, 12, 21, and 47
after infection. The amounts of serum IL-17 in these mice were then assessed by
ELISA. The levels of serum IL-17 in B. burgdorferi-infected mice injected with
isotype control antibodies increased gradually from day 7 (15.5 pg/mL) to day 12
(28.1 pg/mL) to day 21 (47.5 pg/mL). By contrast, the levels of serum IL-17 in
infected mice treated with anti-IFN-γ antibodies increased rapidly from day 7
(19.9 pg/mL) to day 12 (44.9 pg/mL), and then decreased by day 21 (35.6
pg/mL). Infected, anti-IFN-γ-antibody-treated mice had a significantly greater
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amount of serum IL-17 than infected, non-treated mice at day 12 after infection
(P=0.0006; Figure 2). The amount of serum IL-17 in non-infected controls
gradually decreased following injections of BSK and PBS, and no significant
amounts of serum IL-17 were detected in any group at day 47 after infection
(data not shown).

Figure 2. Concentrations of IL-17 in serum of non-infected C3H mice (n=5) and
C3H mice infected with B. burgdorferi 297, with (n=5) or without (n=5)
administration of anti-IFN-γ antibodies, at day 12 after infection. * denotes a
significant difference (P<0.05). Error bars indicate the SEM.

3. Role of sustained infection on production of IL-17
The Borrelia-vaccination and -infection model of Lyme arthritis was used to
investigate whether live B. burgdorferi infection, as opposed to a non-viable
infection, is required for an IL-17 response associated with increased hind-paw
swelling. C3H mice were vaccinated with B. bissettii and later injected with viable
B. burgdorferi 297 organisms, heat-killed B. burgdorferi 297 organisms, or BSK
medium. The swelling of their hind paws was measured. Vaccinated mice
infected with live B. burgdorferi developed significantly greater paw swelling than

24
mice injected with dead B. burgdorferi or medium consistently by day 8 after
infection (p=0.003; Figure 3). All mice were sacrificed at day 10 after these
injections, near the presumed peak swelling time after infection.

Figure 3. Hind paw swelling of Borrelia-vaccinated C3H mice injected with live
(n=16) or heat-killed (n=12) B. burgdorferi 297 (Bb). A control group consisted of
vaccinated mice that were not infected (n=8). * denotes a significant (P<0.05)
difference in paw swelling. Error bars indicate SEM.

From these mice, cell culture supernatants of unseparated inguinal lymph nodes
cells cultured with live B. burgdorferi 297 organisms were measured for IL-17
production. Upon in vitro stimulation with viable B. burgdorferi 297, cells
harvested from Borrelia-vaccinated- and -infected mice produced less, but not
statistically different, levels of IL-17 than stimulated cells obtained from Borreliavaccinated mice injected with non-viable spirochetes or BSK medium (Figure 4).
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Figure 4. Concentrations of IL-17 from culture supernatants of lymph node cells
from Borrelia-vaccinated C3H mice injected with live (n=3) or heat-killed (n=4) B.
burgdorferi 297 (Bb) or BSK medium (n=2). Cells were obtained at day 10 after
infection and restimulated with B. burgdorferi 297. Error bars indicate SEM.

4. Assessment of IL-17 production in different models of Lyme arthritis
Both the Borrelia-infection and Borrelia-vaccination and -infection models of
Lyme arthritis were used to determine the relative abundance of IL-17 produced
by spleen cells after infection with B. burgdorferi. To characterize these
differences, the amounts of IL-17 produced by cells from wild-type C57BL/6 mice
obtained at the peak of swelling in both models were determined. Spleen cells
were collected at day 8 after infection and then incubated with B. burgdorferi 297
for 6 or 24 hours.

Cells obtained from naïve, wild-type mice produced non-detectable levels of IL17 when cultured with B. burgdorferi 297 for 6 hours (Figure 5). Production of IL17 by these cells increased after 24 hours, but the increase did not reach
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statistical significance (P=0.08). Similarly, cells from B. burgdorferi-infected mice
that were restimulated with the spirochete for 6 hours produced low levels of IL17. No difference in IL-17 production was detected after 24 hours (Figure 5).
When comparing IL-17 production between cells from naïve and infected mice
after in vitro stimulation, there were no significant differences observed at either
time point.

Cells obtained from Borrelia-vaccinated, wild-type mice, whether or not the mice
were infected, produced no detectable IL-17 when cultured with B. burgdorferi
297 for 6 hours (Figure 5). However, upon in vitro stimulation with viable B.
burgdorferi 297, cells from vaccinated, non-infected mice produced significantly
more IL-17 after 24 hours (P=0.008; Figure 5). The amount of IL-17 produced
from cells of naïve mice, non-vaccinated but infected mice, and vaccinated-andinfected mice after 24-hour restimulation was significantly lower than the amount
of IL-17 produced from cells of vaccinated, non-infected mice (P=0.008).
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Figure 5. Concentrations of IL-17 from culture supernatants of spleen cells
obtained from naïve (n=7), Borrelia-infected (n=8), Borrelia-vaccinated (n=6),
and Borrelia-vaccinated and –infected (n=6) wild-type (WT) C57BL/6 mice.
Cells were obtained at peak swelling (8 days after the time of infection) and
then stimulated with B. burgdorferi in vitro for 6 or 24 hours. * denotes a
significant difference (P<0.05). ND, not detected. Error bars indicate SEM.

5. Assessment of Borrelia-induced IL-17 production in models of Lyme arthritis in
IL-10-deficient mice
The role of the anti-inflammatory cytokine IL-10 on the production of IL-17 in the
Borrelia-infection and Borrelia-vaccination and -infection models of Lyme arthritis
was characterized. Spleen cells were collected from IL-10-deficient mice of both
models at day 8 after the day of infection and then incubated with B. burgdorferi
297 for 6 or 24 hours.

Spleen cells from naïve, IL-10 knock-out (KO) mice produced low levels of IL-17
following incubation with B. burgdorferi 297 for 6 hours (Figure 6). No significant
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increase was observed after 24 hours of incubation. By contrast, IL-17 production
by spleen cells of Borrelia-infected IL-10 KO mice increased significantly, by
1300% (P=0.005), between 6 and 24 hours of restimulation with B. burgdorferi
297 (Figure 6). In addition, stimulated spleen cells from infected mice produced
greater amounts of IL-17 than stimulated cells from naïve mice at each time
point. The increases at both time points, however, were not significant.

Cells obtained from Borrelia-vaccinated, non-infected IL-10 KO mice produced
low amounts of IL-17 after 6 hours of stimulation with B. burgdorferi 297 (Figure
6). A highly significant increase of 3600% (P=0.002) in IL-17 production was
observed from these cells after 24 hours of incubation. .However, no differences
in IL-17 production were observed between these groups after 24 hours of
incubation with the spirochete.
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Figure 6. Concentrations of IL-17 from culture supernatants of spleen cells
obtained from naïve (n=6), Borrelia-infected (n=8), Borrelia-vaccinated
(n=10), and Borrelia-vaccinated and –infected (n=10) IL-10 knock-out (KO)
C57BL/6 mice. Cells were obtained at peak swelling (8 days after the time of
infection) and then stimulated with B. burgdorferi in vitro for 6 or 24 hours. *
denotes a significant difference (P<0.05). Error bars indicate SEM.

6. Effect of IL-10 deficiency on IL-17 production in models of Lyme arthritis
Using the data described above, the effect of IL-10 deficiency on IL-17
production during the peak phase of swelling following B. burgdorferi infection
was assessed. In both models of infection (non-vaccinated but Borrelia-infected;
Borrelia-vaccinated and -infected) and both control groups (non-vaccinated and
non-infected [naïve]; Borrelia-vaccinated but non-infected), spleen cells of IL-10
KO mice produced more IL-17 when exposed to B. burgdorferi 297 in vitro than
cells of wild-type mice. Naïve IL-10 KO cells displayed higher levels of IL-17 after
6 and 24 hours of incubation (Figure 7), with significantly higher levels detected
after the 6-hour incubation (P=0.05). Similar results were observed from the cells
of Borrelia-infected IL-10 KO mice, with significant increases of IL-17 production
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at 6 hours (2400%, P=0.0003) and at 24 hours (10,700%, P=0.02) compared to
cells of infected wild-type mice (Figure 7).

Figure 7. Concentrations of IL-17 from culture supernatants of spleen cells
obtained from wild-type (WT) and IL-10-deficient (KO), naïve (n=7) and
Borrelia-infected (n=8) C57BL/6 mice. Cells were obtained at peak swelling
(day 8 after the time of infection) and were stimulated with B. burgdorferi in
vitro for 6 or 24 hours. * denotes a significant difference (P<0.05). ND, not
detected. Error bars indicate SEM.

Similarly, significantly greater levels of IL-17 were produced by stimulated spleen
cells of Borrelia-vaccinated, non-infected IL-10 KO mice after 6 hours (P=0.001)
and 24 hours (770%, P=0.02) of incubation compared to stimulated cells of wildtype mice (Figure 8). Also, stimulated spleen cells from Borrelia-vaccinated and infected IL-10 KO mice produced significantly more IL-17 after 6 hours
(P=0.0005) and 24 hours (3300%, P=0.01) of incubation compared to cells from
wild-type mice.
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Figure 8. Concentrations of IL-17 from culture supernatants of spleen cells
obtained from wild-type (WT) and IL-10-deficient (KO), Borrelia-vaccinated (n=8)
and Borrelia-vaccinated and –infected (n=8) C57BL/6 mice. Cells were obtained at
peak swelling (day 8 after the time of infection) and were stimulated with B.
burgdorferi in vitro for 6 or 24 hours. * denotes a significant difference (P<0.05).
ND, not detected. Error bars indicate SEM.

7. Anti-CD4 antibody modulation of IL-17 in models of Lyme arthritis
Here, the contribution of CD4-expressing cells to the production of IL-17 in the
Borrelia-infection and Borrelia-vaccination and -infection models of Lyme arthritis
was assessed. Spleen cells were harvested at the peak of swelling from wildtype and IL-10-deficient mice and incubated for 6 and 24 hours with B.
burgdorferi, with or without anti-CD4 antibodies. Data from cells incubated
without anti-CD4 antibody have been shown previously (Figures 5-8).

No differences in IL-17 production due to anti-CD4 antibodies were observed
among stimulated cells from naïve, wild-type mice at either 6 or 24 hours of
incubation (Figure 9). By contrast, after 24 hours of incubation with anti-CD4
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antibodies, stimulated cells from non-vaccinated, B. burgdorferi-infected wild-type
mice produced 86% less IL-17 than stimulated cells not exposed to antibodies
(Figure 9); this difference was significant (P=0.03). These results were not
observed after 6 hours of incubation. Also, after 24 hours of incubation with antiCD4 antibodies, stimulated spleen cells from Borrelia-vaccinated, non-infected
wild type mice produced 44% less IL-17 than cells not incubated with antibodies.
However, this decrease was not significant (P=0.10; Figure 9). No changes in IL17 production were detected following anti-CD4 antibody treatment of stimulated
cells obtained from Borrelia-vaccinated and -infected wild-type mice at either time
point.

Figure 9. Concentrations of IL-17 from culture supernatants of spleen cells from
naïve (n=6), Borrelia-infected (n=8), Borrelia-vaccinated (n=6), and Borreliavaccinated and –infected (n=6) wild-type (WT) C57BL/6 mice. Cells were
obtained at peak swelling (day 8 after the time of infection) and then stimulated
with B. burgdorferi 297 (Bb), with or without anti-CD4 antibody (αCD4). * denotes
a significant difference (P<0.05). ND, not detected. Error bars indicate SEM.
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The effects of anti-CD4 antibodies on IL-17 production were also assessed
among stimulated spleen cells obtained from IL-10 KO mice. No differences in IL17 production due to anti-CD4 antibodies were observed among stimulated cells
from naïve IL-10 KO mice, Borrelia-infected IL-10 KO mice, or Borreliavaccinated, non-infected IL-10 KO mice after either 6 or 24 hours of

incubation

(Figure 10). By contrast, a statistically significant decrease (56%, P=0.006) in IL17 production was observed among stimulated, anti-CD4 antibody-treated cells
from Borrelia-vaccinated and -infected IL-10 KO mice at 6 hours of incubation.
However, no differences in IL-17 production were exhibited at 24 hours of
incubation.

Figure 10. Concentrations of IL-17 from culture supernatants of spleen cells
from naïve (n=6), Borrelia-infected (n=8), Borrelia-vaccinated (n=10), and
Borrelia-vaccinated and –infected (n=10) IL-10 deficient (KO) C57BL/6 mice.
Cells were obtained at peak swelling (day 8 after the time of infection) and then
stimulated with B. burgdorferi 297 (Bb), with or without anti-CD4 antibody
(αCD4). * denotes a significant difference (P<0.05). Error bars indicate SEM.
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II. Specific Aim 2: Establish a relationship between IL-17 levels and
borreliacidal antibody production.
1. Borreliacidal antibody titers following sustained infection with B. burgdorferi
The data presented previously indicate that stimulation of lymph node cells from
Borrelia-vaccinated C3H mice infected with live B. burgdorferi 297 resulted in
less IL-17 production than stimulation of cells from Borrelia-vaccinated mice
injected with non-viable spirochetes. Therefore, borreliacidal antibody titers were
assessed from cell culture supernatants in order to examine increased microbe
killing in vitro as a possible reason for these unexpected results. Lymph node
cells from Borrelia-vaccinated, non-infected mice, incubated with B. burgdorferi
297 in vitro, produced a borreliacidal antibody titer of 640 against B. burgdorferi
297 (Figure 11). By contrast, cells from Borrelia-vaccinated mice injected with
viable or heat-killed B. burgdorferi 297 both produced significantly higher titers of
borreliacidal antibody, which exceeded the detection ability of the assay (≥
10,240).
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Figure 11. Borreliacidal antibody titers from culture supernatants of lymph
node cells from Borrelia-vaccinated C3H mice injected with live (n=8) or
heat-killed (n=6) B. burgdorferi 297 or BSK medium (n=4). Cells were
obtained at the peak of swelling (day 10 after the time of injections) and
stimulated with B. burgdorferi 297 in vitro for 24 hours. * denotes a
significantly greater (4-fold) titer than that of cells from non-infected mice.

2. Effect of IL-10 on borreliacidal antibody titers in models of Lyme arthritis
Hind paws of IL-10 KO, C57BL/6 mice developed greater swelling after infection
with B. burgdorferi than their wild-type counterparts (data not shown). The cells
of these mice also had a greater IL-17-producing capacity following in vitro
exposure to the spirochete than wild-type cells (Figures 5-8). Borreliacidal
antibody titers were measured from the sera of these mice at the peak of paw
swelling to examine the effect of IL-10 on a possible mechanism responsible for
clearing infection. As expected, naïve, wild-type mice possessed a low level of
borreliacidal antibody against B. burgdorferi 297 (titer, 10; Figure 12). Absence of
IL-10 caused a significant (8-fold) increase in titers. However, these titers were
still very low. Absence of IL-10 slightly, but insignificantly, increased the
borreliacidal antibody titers in non-vaccinated, B. burgdorferi 297-infected mice
(titer, 40) compared to wild-type mice (titer, 20). Lack of IL-10 in Borrelia-
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vaccinated, non-infected mice significantly increased the borreliacidal antibody
titers (titer, ≥10,240) against B. burgdorferi 297 compared to wild-type mice (titer,
640). The titers of borreliacidal antibody in Borrelia-vaccinated and -infected
mice, regardless of strain, exceeded the levels of detection in the assay
(≥10,240).

Figure 12. Borreliacidal antibody titers obtained from sera of naïve (n=4), Borreliainfected (n=4), Borrelia-vaccinated (n=4), and Borrelia-vaccinated and -infected
(n=4) wild-type (WT) and IL-10-deficient (KO) C57BL/6 mice at the peak of hind paw
swelling (day 8 after the time of infection). * denotes a significantly greater (4-fold)
titer than wild-type counterparts.
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CHAPTER 4: DISCUSSION
This thesis contributes to knowledge of how IL-17 is involved in the inflammatory
response to B. burgdorferi. IL-17 is a pro-inflammatory cytokine that is produced
in response to B. burgdorferi infection (35) and is associated with various forms
of arthritis (37-40). Recent studies have also characterized the role of IL-17 and
related cytokines in the development of Lyme arthritis, leading to the hypothesis
that Th17 cells are a potential contributor to disease (45). In addition, since IL-17
is produced by other cell types in addition to Th17 cells (21, 69), the contribution
of potential Th17 cells to the production of IL-17 in response to B. burgdorferi is
unknown. Also, whether IL-17 is associated with the protective borreliacidal
antibody response has not been fully examined. The objective of this thesis was
to elucidate the contributions of IL-17-producing CD4+ cells in the development
of B. burgdorferi-induced arthritis and IL-17 in the stimulation of the borreliacidal
antibody response. The following specific aims were pursued to test this
hypothesis: (1) Establish CD4+ cells as a source of IL-17 following infection with
B. burgdorferi; (2) Establish a relationship between IL-17 levels and borreliacidal
antibody production.

I. Specific Aim 1: Establish CD4+ cells as a source of IL-17 following
infection with B. burgdorferi.
Th17 and Th1 cells have been shown to have an antagonistic relationship though
the effects of IL-17 and IFN-γ, respectively (50). In order to explore the role of IL17 in a reduced Th1 environment during Lyme arthritis, mice were infected with
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B. burgdorferi 297 and then injected with anti-IFN-γ antibody. These mice
developed similar degrees of paw swelling than B. burgdorferi-infected, isotype
antibody-treated controls (Figure 1). However, a greater degree of peak paw
swelling was observed, although this difference was not statistically significant
(Figure 1). Additionally, the serum of Borrelia-infected mice treated with anti-IFNγ antibody contained greater levels of IL-17 than non-treated, infected controls
(Figure 2). These results are consistent with previous findings in which mice
genetically deficient in IFN-γ, its receptor, or its signaling pathway can develop
Lyme arthritis (29, 30, 31), which demonstrates that IFN-γ is not the sole cytokine
responsible for the development of pathology. Furthermore, these findings
provide additional support for the antagonistic relationship between Th1 and
Th17 cells (50). They also support findings in Borrelia-infected mice that
demonstrated an increase in IFN-γ following treatment with anti-IL-17 antibodies
(70). The results presented here are consistent with these data by displaying this
inverse relationship, since anti-IFN-γ antibody treatment led to an increase in IL17 production (Figure 2). Non-infected control mice also produced low levels of
IL-17 (Figure 2). This is most likely due to the daily injections of PBS that these
mice received. The repeated trauma would likely produce a mild inflammatory
response, resulting in low levels of IL-17.

These data also fit with research establishing IL-17 as a contributor to Lyme
arthritis using the Borrelia-vaccination and -infection model of disease, which
reflects later-stage arthritis in humans through its significant involvement of CD4+
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T cells (32, 33). Christopherson, et al. showed that Borrelia-vaccinated and infected C57BL/6 mice lacking IFN-γ (i.e., the Th1 response) developed severe,
destructive arthritis (30), pointing to the involvement of other inflammatory
mechanisms. IL-17, which recently had been shown to be produced by helper T
cells in response to B. burgdorferi (35), was investigated as a possible cause of
Lyme arthritis. Treatment of Borrelia-vaccinated and -infected IFN-γ KO mice
with anti-IL-17 antibodies at the time of infection for 11 days (43) or 7 days (49)
prevented the development of arthritis. In addition, treatment of wild-type
C57BL/6, Borrelia-vaccinated and -infected mice with anti-IL-17 antibodies
reduced the severity of pathology (45), although not to the level observed in
treated IFN-γ KO mice (43, 49). This shows that IFN-γ may be an important
regulator of IL-17, possibly from T cells, in Lyme arthritis.

Following these earlier findings in the context of B. burgdorferi infection, Park, et
al. (34) described the existence of a unique subpopulation of IL-17-producing
CD4+ T cells (Th17 cells). Bettelli, et al. (44) then showed that the development
of these cells from naïve T cells in vitro required a combination of IL-6 and TGFβ. Veldhoen, et al. extended this observation to show that TGF-β, in the
presence of inflammatory mediators (IL-1β, IL-6, TNF-α), leads to Th17
differentiation (71). Also, survival of Th17 cells was shown to require stimulation
with IL-23 (44). IL-23 is also required for full differentiation of Th17 cells (72) and
is also induced by B. burgdorferi stimulation (46). Using the Borrelia-vaccination
and -infection model in wild-type C57BL/6 mice, it was shown that neutralization
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of IL-23 prevented arthritis and was required for IL-17 production in vitro (47). In
addition, injection of infected mice with a combination of anti-IL-6 and anti-TFG-β
antibodies reduced arthritic pathology (45). Codolo, et al. (48) provided direct
evidence that Th17 cells are found in the joints of human Lyme arthritis patients.
Specifically, neutrophil activating protein A of B. burgdorferi causes the release of
IL-6, IL-1β, TGF-β, and IL-23 from various innate cells, which work together to
stimulate synovial T cells to produce IL-17 (48). The findings presented here
provide additional support that T cells are a possible source of IL-17 during the
peak arthritic stage after infection with B. burgdorferi. However, direct evidence
of a role for Th17 has not yet been shown.

Conflicting evidence exists for a role for Th17 cells in Lyme arthritis. Th17 cells
were also found in the synovial fluid and tissues of humans with disease by
Shen, et al. (28). However, they found the Th17 population to only comprise
approximately 10% of the CD4+ T cell population in most patients (28). They did
not examine the arthritic potential of these cells, but concluded that they may not
contribute to disease. Consistent with this study, Oosting, et al. (73) showed that
some humans possess a polymorphism of the IL-23 receptor that causes
defective binding of the cytokine. Humans with this polymorphism who are also
infected with B. burgdorferi produce less IL-17 than those without the
polymorphism, but the severity of their arthritis does not differ (73). However,
these data were collected with relatively low sample sizes in humans (28, 73).
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The natural variation in humans, coupled with these low sample sizes, prevents
absolute conclusions from being made.

In order to determine whether established Borrelia infection was required to
stimulate this inflammatory cascade, vaccinated mice were challenged with either
live or heat-killed B. burgdorferi 297. Borrelia-vaccinated mice infected with live
organisms developed significantly greater swelling at peak disease (Figure 3).
Unexpectedly, unseparated lymph node cells from these mice, following
restimulation with B. burgdorferi 297 (the microbe of infection), produced less
IL-17 than stimulated cells obtained from vaccinated mice injected with heatkilled organisms (Figure 4). These surprising results may have occurred due to
differences in the immune response to primary versus secondary exposure to live
organisms. The first exposure of cells from Borrelia-vaccinated mice injected with
heat-killed spirochetes to live B. burgdorferi 297 occurred in culture. By contrast,
lymph node cells from Borrelia-vaccinated, B. burgdorferi 297-infected mice had
already been exposed to the live bacteria and were encountering it for the
second time while in culture. Since secondary, ex vivo exposure decreased IL-17
production, it was thought that this restimulation may have caused a robust
borreliacidal antibody response from B cells present in the unseparated lymph
node cultures (examined in Specific Aim 2 below). Rapid stimulation of
borreliacidal antibodies may have cause the killing of the bacteria in culture,
resulting in a reduced antigenic stimulus and less IL-17 production.
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By contrast, Ganapamo et al. (74) investigated the cytokine response to B.
burgdorferi strain JD1 infection by simulating lymph node cells of infected mice
with the same isolate in vitro. However, these mice were not vaccinated before
infection, unlike the mice used in these studies. It was previously shown that cells
from B. bissettii-vaccinated, non-infected mice produced cytokines associated
with Th17 cells when exposed to B. burgdorferi 297 for the first time in vitro (47,
75). These studies, with the data presented here, show that a secondary
exposure to a live B. burgdorferi strain in vitro, using the Borrelia-vaccination and
-infection model, likely do not yield cytokine results that reflect primary infection.
However, this secondary exposure may allow for examination of the borreliacidal
antibody response, given that B cells in these unseparated cell cultures may be
highly activated.

To further explore the role of adaptive immune sources of IL-17, we examined
the effects of the Borrelia-infection and Borrelia-vaccination and -infection models
on the production of the cytokine. Researchers typically use the Borrelia-infection
model of Lyme arthritis, in which C3H, “arthritis-susceptible” mice, are infected
with Borreliae (56). This model, however, favors the events of innate immunity,
which may not appropriately mimic the adaptive immune response involvement
seen in humans with later-stage disease (70). The Borrelia-vaccination and infection model addresses this issue by priming and activating T cells, resulting in
a stronger adaptive immune response (70). Spleen cells harvested from mice at
peak swelling were used to evaluate IL-17 production in vitro. Cells from naïve
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and Borrelia-infected wild-type mice produced low levels of IL-17 upon incubation
with live B. burgdorferi 297, with little change occurring between the 6 and 24
hour incubations (Figure 5). These results were expected, considering that the
Borrelia-infection model may not fully reflect the involvement of IL-17 following B.
burgdorferi infection (70). By contrast, cells from Borrelia-vaccinated, noninfected mice produced significantly higher levels of IL-17 after 24 hours in
culture (Figure 5). These results are consistent with the rationale behind the use
of the Borrelia-vaccination and -infection model, which primes T cells at
vaccination and involves a greater adaptive immune response, especially the
adaptive IL-17 response, upon infection with live organisms (70). Cells from
Borrelia-vaccinated and -infected mice also produced higher, but not significantly
greater, levels of IL-17 at the 24 hour incubation time point (Figure 5). These
levels, however, were lower than those seen in the stimulated cells from Borreliavaccinated, non-infected mice. This again points to the possible differences in the
development of borreliacidal antibodies occurring in primary versus secondary
exposure. Regardless, cells from Borrelia-vaccinated, but non-infected mice had
greater levels of IL-17 than cells from naïve, non-vaccinated, but B. burgdorferiinfected, and Borrelia-vaccinated and -infected mice, supporting the hypothesis
that the Borrelia-vaccination and -infection model of disease better reflects the
involvement of IL-17 in the response to the spirochete (70).

Additionally, IL-10-deficient mice on a C57BL/6 background have been proposed
as another model of Lyme arthritis (76). This is due, in part, to the involvement of
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T cells that lead to a sustained IFN-γ response, which reflects the persistent
arthritis that occurs in humans (76). Wild-type C57BL/6 mice are typically
resistant to arthritis and, generally, produce more IL-10 in response to Borrelia
exposure (29). Conversely, susceptibility to developing Lyme arthritis has been
linked to an early production of IL-10 after infection with B. burgdorferi, which
regulates the effects of IFN-γ (74), macrophages (77), and macrophage signaling
pathways (78) in the response to infection. IL-10 also has been shown to inhibit
the production of IL-17 by Th17 cells (79). However, the effect of IL-10 on IL-17
production in Lyme arthritis has not been investigated.

Here, the production of IL-17 in the different models was compared. Cells from
non-vaccinated, Borrelia-infected IL-10 KO mice produced highly increased
levels of IL-17 between 6 and 24 hours of in vitro stimulation (Figure 6), a change
that was not seen in wild-type counterparts (Figure 5). These IL-10 KO cells
produced significantly more IL-17 than wild-type cells at both time points (Figure
7). Similarly, stimulated cells from Borrelia-vaccinated, non-infected IL-10 KO
mice produced amounts of IL-17 which were significantly greater than wild-type
counterparts at both time points (Figure 8).

In general, stimulated spleen cells from all IL-10 KO groups developed greater
levels of IL-17 (Figure 8) and hind paw swelling (data not shown) than their wildtype counterparts. As expected, this indicates that the presence of IL-10, an antiinflammatory cytokine, inhibits the production of IL-17. In support of these
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findings, IL-10 directly inhibits the activity of Th17 cells and T cells that produce
both IL-17 and IFN-γ in a model of colitis (79). In terms of Lyme arthritis,
specifically, these findings are also consistent with those of others. B.
burgdorferi-infected IL-10 KO mice retain more spirochetes in their tissues (80)
and develop greater paw swelling (76) than infected wild-type mice. This lack of
IL-10 was associated with increased levels of IFN-γ, and neutralization of this
IFN-γ reduced inflammation (76). These researchers did not examine the effects
of IL-10 deficiency on IL-17, however. Here, we show that IL-10 deficiency
increases levels of IL-17 following infection with B. burgdorferi, and future studies
will assess the contribution of IL-17 to arthritis in these mice. The findings here,
which show an additional effect of IL-10 on inflammation caused by a known
helper T cell cytokine, support the hypothesis that IL-17 formed in response to B.
burgdorferi infection may be derived from CD4+ T cells.

To obtain additional support for this, CD4 was blocked in in vitro cultures of
stimulated spleen cells obtained at peak swelling in different models of Lyme
arthritis. This was done to assess the contribution of IL-17-secreting CD4+ cells
(likely Th17 cells) in the different models of disease. Significant decreases in the
production of IL-17 were induced following administration of an anti-CD4
antibody in stimulated cells from Borrelia-infected, wild-type mice (Figure 9). This
exposure to live organisms likely resulted in an increased CD4+ T cell (potentially
Th17 cell) response that was sensitive to the effects of the antibody. In addition,
cells from vaccinated, but not infected, wild-type mice also trended toward a
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decrease in IL-17 with exposure to anti-CD4 antibody, though this decrease was
not statistically significant (Figure 9). A significant decrease in IL-17 following
anti-CD4 antibody treatment was expected in this group, as the in vitro culture
was these vaccinated cells’ primary exposure to live B. burgdorferi 297. As
anticipated, significant IL-17 production was observed following this activation of
vaccine-primed cells by a heterologous strain. Therefore, it may be that the
amount of anti-CD4 antibody used was not sufficient to fully counter the level of
Th17 cell activation and IL-17 production. Still, however, these data do point to
the possible presence of Th17 cells stimulated by B. burgdorferi. In addition,
other IL-17-producing cells may be induced by B. burgdorferi, since addition of
anti-CD4 antibodies to cultures did not completely abrogate IL-17 production.

Cells from Borrelia-vaccinated and -infected IL-10 KO mice did achieve a
significant reduction in IL-17 in the presence of anti-CD4 antibody after 6 hours in
culture (Figure 10). Considering that the lack of IL-10 in these cells could
naturally skew towards a Th17 response after encountering antigen, these data
are not surprising. In addition, since this decrease was not observed in cells from
wild-type Borrelia-vaccinated and -infected mice (Figure 9), this may indicate just
how powerful the effect of IL-10 is in inhibiting a Th17 response. However, no
similar effect was observed in stimulated cells from non-vaccinated, Borreliainfected IL-10 KO mice or Borrelia-vaccinated, non-infected IL-10 KO mice. This
may have resulted from the substantial amount of IL-17 produced by these cells,
which may have been too great to counter with the amount of anti-CD4 antibody
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used. A large amount of cell activation seems to have occurred in both of these
groups upon in vitro stimulation for 24 hours. As previously stated, the increase
in IL-17 production by cells from the Borrelia-vaccinated, non-infected IL-10 KO
mice may be due to the primary exposure of these cells to the in vitro antigen, B.
burgdorferi 297. However, non-vaccinated, Borrelia-infected IL-10 KO mice were
challenged with B. burgdorferi 297, yet still contained cells that produced
significant IL-17 during in vitro exposure to B. burgdorferi 297 (Figure 10). This
may provide additional support that the Borrelia-infection model of Lyme arthritis
does not reflect the in vivo IL-17 response well. However, this also points to the
possibility that prior vaccination with B. bissettii may prime mice to robustly
produce borreliacidal antibody against B. burgdorferi 297 following infection with
this latter strain. In support of this, less IL-17 was observed in restimulated cells
from Borrelia-vaccinated and -infected mice IL-10 KO mice than from infected IL10 KO mice that were not vaccinated (Figure 10). The effect of prior vaccination
seems to affect the strength of the response to secondary antigen exposure. In
any case, these data in IL-10 KO mice provide support that IL-17 may influence
disease in Lyme arthritis. Also, Th17 cells may be a source of IL-17, though it is
likely not the only source, as anti-CD4 antibody did not completely prevent
production of IL-17. In future experiments, a dose-response experiment with antiCD4 antibody will be performed to account for the considerable IL-17 levels seen
in these groups.
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In summary, the working hypothesis for this aim was CD4+ cells are a significant
source of IL-17 during B. burgdorferi-induced inflammation. These data provide
support to this hypothesis. Known relationships between Th1 and Th17 cells, as
well as between IL-10 and Th17 cells, were demonstrated following infection with
B. burgdorferi. Importantly, these relationships were demonstrated at the peak of
swelling in different Lyme arthritis models. In addition, CD4-expressing cells were
shown to be involved in the production of IL-17 at the peak of swelling. One
possible confounding factor was the unexpectedly low amount of IL-17 produced
following secondary exposure to B. burgdorferi 297. However, this is explored in
Specific Aim 2 and is discussed below.

II. Specific Aim 2: Establish a relationship between IL-17 levels and
borreliacidal antibody production.
A potent antibody response is required for protection against B. burgdorferi
infection and the ensuing inflammation. Th17 cells have been shown to exert
effects on the ability of B cells to produce antibody (81). For example, Th17 cells
induce the production of autoantibodies that contribute to experimental arthritis
(82). In addition, IL-21, a product of Th17 cells, contributes to the IL-6-mediated
antibody response (83). In addition, IL-17 has been shown to stimulate classswitching in response to infection (84). Furthermore, B. burgdorferi-primed T cells
have been shown to influence borreliacidal antibody production (85). However,
the role of IL-17 in the antibody response to B. burgdorferi is not fully known.

49
As stated above, the effects of viable B. burgdorferi infection, as opposed to nonviable infection, on IL-17 production during peak swelling were investigated.
Surprisingly, whole lymph node cells from Borrelia-vaccinated mice infected with
live B. burgdorferi 297, restimulated with B. burgdorferi 297, produced less IL-17
than stimulated cells obtained from vaccinated mice injected with heat-killed
organisms. This unexpected result may have occurred due to significant priming
of borreliacidal antibody-producing B cells in vaccinated mice given a live
infection. It was hypothesized that the in vitro exposure to B. burgdorferi
stimulated a strong borreliacidal response in those vaccine-primed cells that had
already interacted with B. burgdorferi 297 in vivo. These antibodies would have
cleared the in vitro infection, removing the stimulus for IL-17 production. Since
unseparated lymph node populations were used to assess cytokine levels in
these mice, the association of IL-17 with development of the borreliacidal
antibody response was investigated.

B. burgdorferi 297-stimulated cells from Borrelia-vaccinated, non-infected mice
produced low levels of borreliacidal antibodies (Figure 11). Unexpectedly,
supernatants of restimulated cells from Borrelia-vaccinated mice injected with
either viable or heat-killed B. burgdorferi 297 revealed high levels of borreliacidal
antibody production (Figure 11). Unfortunately, whether or not the titers differed
between these groups could not be determined, as the titers exceeded the level
of detection in the assay. While these antibodies are stimulated by the presence
of heat-killed bacteria, these results may also indicate that live infection induced
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the production of borreliacidal antibodies which prevented a robust IL-17
response in the in vitro system used here. Although stimulation of cells obtained
from mice injected with heat-killed organisms also induced a high titer, an IL-17
response also developed. These cells may have initially produced borreliacidal
antibodies only upon primary exposure to live organism in vitro, while the cells
from mice infected with live organism had already been producing these
antibodies in vivo for 10 days. If this is the case, it is possible that the IL-17
response developed prior to the significant production of protective antibodies,
and that the prior existence of these antibodies inhibited the IL-17 response.

Th17 cells may also contribute to the development of borreliacidal antibodies. IL6, a cytokine that supports Th17 cell differentiation (86), promotes the production
of borreliacidal antibodies against immunodominant Borrelia epitopes in vitro (87,
88). In addition, borreliacidal antibody titers are increased following in vitro
neutralization of IFN-γ (89), which appears to be antagonistic to IL-17 in Lyme
arthritis. It is shown here that Borrelia-infected mice treated with anti-IFN-γ
antibodies produced more IL-17 during peak swelling, which may suggest that
the corresponding increase in IL-17 may also contribute to borreliacidal antibody
production. By contrast, treatment of Borrelia-vaccinated and -infected mice with
antibodies against combinations of IL-17, IL-6, and TGF-β yielded borreliacidal
antibody titers that did not fully correlate with disease outcome (45). Therefore,
the timing of borreliacidal antibody production and induction of IL-17 may
coincide, and each may affect the other.
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Here, lower titers of borreliacidal antibodies in naïve wild-type mice, compared to
naïve IL-10 KO mice, were observed (Figure 12). The increased levels of
antibodies observed in the serum of IL-10 KO mice, despite lack of previous
exposure to the organism, demonstrate the significance of IL-10 in borreliacidal
antibody production. IL-10 KO mice also produced significantly greater levels of
borreliacidal antibodies than their wild-type counterparts in the Borreliavaccinated, non-infected group (Figure 12). These results are consistent with
data demonstrating that large amounts of IL-10 suppress the proliferation and
differentiation of certain types of B cells (90). Previous research has also shown
that deficiency of IL-10 leads to increased borreliacidal antibody titers in vivo
following infection with B. burgdorferi (80). However, these researchers reported
that increased microbial clearance resulted from an enhanced innate immune
response, rather than from the increased titers of borreliacidal antibodies (80).
These findings are also consistent with our results. If IL-10 increases
borreliacidal antibody production and IL-17 production, this IL-17 may also be
produced by activated innate cells, including populations of neutrophils, dendritic
cells, and/or natural killer cells. This is plausible, since it is shown here that cells
other than CD4+ cells produce IL-17, as blocking CD4 did not completely inhibit
production of the cytokine.

In summary, the working hypothesis for this aim was increases in IL-17 are
associated with an increase in borreliacidal antibody titers following infection with
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B. burgdorferi. The data shown here partially support this hypothesis; however,
an association between IL-17 and borreliacidal antibodies induced following
infection of mice with live or dead B. burgdorferi was unable to be established.
This may be due to the fact that the borreliacidal antibody titers exceeded the
detection ability of the assay. This detection ability can be remedied in the future
by creating additional dilutions for examination. In addition, infected IL-10 KO
mice produced greater amounts of borreliacidal antibody and possessed cells
that produced greater amounts of IL-17 upon in vitro culture. While an
association can be made between increased IL-17 and increased borreliacidal
antibodies, it is likely that the genetic deficiency in IL-10 is the major contributor.

However, an association between IL-17 and borreliacidal antibody production
may be observed in the wild-type mice used here. , In vitro-stimulated cells from
Borrelia-vaccinated, non-infected wild-type mice produced larger amounts of IL17 than stimulated naïve cells and stimulated cells from Borrelia-infected mice
after 24 hours of incubation (Figure 5). These mice also had significantly higher
serum borreliacidal antibody titers than either group (Figure 12). However, while
Borrelia-vaccinated and -infected wild-type mice produced high borreliacidal
antibody titers than other groups (Figure 12), stimulated, unseparated lymph
node cells from these mice produced lower-than-expected amounts of IL-17
(Figure 5). This may be due to the presence of the borreliacidal antibodies in the
in vitro cultures, showing that a relationship between borreliacidal antibodies and
IL-17 production may exist. A future study to further examine this relationship
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would be to administer anti-IL-17 antibodies to wild-type and IL-10 KO mice using
both of these Lyme arthritis models, and then observe the borreliacidal antibody
response. A previous investigation of this, using wild-type C57BL/6 mice, B.
burgdorferi 297 as the vaccine strain, and B. bissettii as the infection strain, led
inconclusive results pertaining to a relationship between borreliacidal antibody
titers and the presence of Th17 cytokines (45). However, in that study, blocking
IL-17 and the Th17-differentiating cytokines IL-6 and TGF-β completely inhibited
the borreliacidal antibody response, demonstrating that Th17 cells and
borreliacidal antibody production may be linked. Further studies are needed to
further elucidate the relationship between IL-17 and the production of
borreliacidal antibodies..
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CHAPTER 5: CONCLUSION AND FUTURE DIRECTIONS
The hypothesis for this thesis was that IL-17 produced by CD4+ cells contributes
to the inflammation associated with B. burgdorferi infection and is associated with
an increase in borreliacidal antibody production. The first aim, to establish CD4+
cells as a source of IL-17 following infection with B. burgdorferi, was supported.
Using different models of Lyme arthritis, the data presented here supported
known relationships between Th1 and Th17 cells as well as between IL-10 and
Th17 cells. Production of IL-17 increased following B. burgdorferi infection and
was prominent at the peak of hind paw swelling. At this peak swelling period, IL17 production was regulated by both IFN-γ and IL-10, and was produced, in part,
by CD4+ cells. It is likely that Th17 cells are contributing to the development of
Lyme arthritis through their production of IL-17. The second specific aim, which
was to establish a relationship between IL-17 levels and borreliacidal antibody
production, was partially supported. As levels of IL-17 increased in both wild-type
mice and IL-10 KO mice infected with B. burgdorferi, an increase in the
production of borreliacidal antibodies was observed. However, additional
research is required to better characterize the role of IL-17 in this process.

Overall, these findings provide additional evidence to support consideration of
inflammatory cytokines other than IFN-γ as contributors to Lyme arthritis
following infection with B. burgdorferi. This may lead to new targets for therapy
against Lyme arthritis. One future study to more directly examine the role of IL-17
following B. burgdorferi infection will be conducted by administering anti-IL-17
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antibodies to wild-type and IL-10 KO mice using both the Borrelia-infection and
Borrelia-vaccination and -infection Lyme arthritis models, and then observing the
borreliacidal antibody response and joint histopathology that result. Future
studies are also needed to determine the role of additional sources of IL-17,
including neutrophils and γδ-T cells (21, 69), following borrelial infection. In
addition, experiments are planned to determine the actual abundance of Th17
cells in B. burgdorferi-infected mice and to determine their contribution to Lyme
arthritis.

However, recent findings show that T cell populations are not as well defined as
is commonly presented, which confounds investigations pertaining to Th17 cells.
Depending on the cytokine environment during development, Th17 cells are able
to convert into both Th1- and Treg-like cells (52). For example, some Th17 cells
may also produce IFN-γ, giving them characteristics of Th1 cells. IL-17+IFN-γ+
Th17 cells are more prominent in autoimmune diseases and, perhaps not
surprisingly, suppress traditional IL-17+IFN-γ- Th17 cells (91). In addition,
populations of Th17 cells can also produce IL-10 (52), thereby potentially
regulating the immune response in the same manner as Treg cells. Future studies
will require consideration of these newly discovered T cell phenotypes in
investigation of B. burgdorferi infection and Lyme arthritis. Importantly, this also
opens a line of research into the modulation of T cells for therapy for, or
prevention of, Lyme arthritis.
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The findings presented here support a potential role for Treg cells in the regulation
of Lyme arthritis. Specifically, CD4+CD25+Foxp3+ Treg cells are critical for
maintaining tolerance and managing autoimmune diseases, in part, through
secretion of IL-10 (92). Bettelli et al. (44) published the major finding that Th17
and CD4+CD25+Foxp3+ regulatory T cells are derived from a common precursor
T cell, with the presence or absence of a certain inflammatory cytokine
environment determining the outcome of differentiation. Prior to this finding, an
association between IL-17 and presumed Treg cells was described in the
development and regulation of Lyme arthritis, using IFN-γ-deficient, Borreliavaccinated and -infected mice (49). Neutralization of IL-17 in these mice, in
addition to preventing the development of arthritis, led to an increase in the
numbers of CD4+CD25+ T cells in the local lymph nodes (49). Depletion of
CD25+ cells in anti-IL-17 antibody-treated, Borrelia-vaccinated and -infected
mice led to severe, destructive arthritis (49). In addition, transfer of CD4+CD25+
cells obtained from these anti-IL-17 antibody-treated mice into infected recipient
mice protected against arthritis development (93). By contrast, transfer of
CD4+CD25- T cells into infected recipients increased disease severity (93).
Moreover, depletion of CD4+CD25+ T cells in Borrelia-vaccinated and -infected
mice not administered anti-IL-17 antibodies did not affect arthritis (94),
suggesting that the absence of IL-17 induced a distinct subpopulation of
CD4+CD25+ T cells that protected against the induction of Lyme arthritis.
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Additional data support a role for Treg cells (and, by extension, Th17 cells), in
Lyme arthritis. Mice deficient in CD28, a co-stimulatory molecule for Treg cells,
displayed intensified and chronic arthritis in response to infection with B.
burgdorferi (95). Shorter duration to resolution of disease has also been
associated with higher percentages of Treg cells in patients with Lyme arthritis
(28). By contrast, patients with antibiotic-refractory Lyme arthritis had lower
percentages of Treg cells and displayed an inability to resolve synovial
inflammation (28). However, Kuo et al. demonstrated that administration of
recombinant interleukin 35 (IL-35), another anti-inflammatory cytokine produced
by Treg cells, to B. burgdorferi-vaccinated and -infected mice actually increased
the severity of Lyme arthritis and decreased borreliacidal antibody titers (96).
Collectively, these findings point to Treg cells as a significant factor in the
regulation of Lyme arthritis. Since Th17 cells are closely related to these cells,
investigation of both cell types is needed for a complete examination of the
immune response to B. burgdorferi infection.

Due to the large increases in production of IL-17 after 24 hours of cell culture by
the cells obtained at the peak of hind paw swelling shown here, it is also
important to consider the production of the cytokine at earlier time points in the
development of arthritis. Preliminary data indicate that IL-17 may play a
significant role early in infection. Cells obtained from mice one day after infection
produced significant levels of IL-17 (data not shown). These levels were reduced
upon addition of anti-CD4 antibody, regardless of infection model (data not

58
shown). Incubation of stimulated cells with anti-CD4 antibody also reduced IFN-γ
in these cells (data not shown), further demonstrating that both inflammatory
cytokines may contribute to Lyme arthritis.
Understanding the immune mechanisms of Lyme arthritis, particularly the role of
IL-17, is necessary for the development of safe vaccines for Lyme borreliosis.
Currently, OspA and outer surface protein C (OspC) are the most commonly
considered vaccine candidates for Lyme borreliosis. While OspA has been
shown to induce borreliacidal antibody titers, it may also induce an autoimmune
response (57). In fact, Croke et al. showed that vaccination of hamsters with
OspA primed the animals for development of severe Lyme arthritis following
infection with B. burgdorferi (97). These findings fueled concern regarding the
safety of OspA vaccines in humans (64). The data presented here suggest that a
successful vaccinate candidate needs to elicit high borreliacidal antibodies titers
without inducing an IL-17 response in order to confer immunity without the
induction of arthritis.

In conclusion, IL-17 has been shown to play a role in the development of Lyme
arthritis. Here, a role for CD4+ cells as a major producer of IL-17 following
infection with B. burgdorferi is supported. Additionally, a relationship between IL17 and borreliacidal antibodies may exist. Future studies will be needed to more
completely characterize the immune response to B. burgdorferi and the
development of Lyme arthritis. However, the findings presented here have
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significant implications for the development of both therapeutic interventions and
safe, effective vaccines against Lyme borreliosis.
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